161 related articles for article (PubMed ID: 33880362)
1. Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice.
Daei Farshchi Adli A; Jahanban-Esfahlan R; Seidi K; Farajzadeh D; Behzadi R; Zarghami N
Adv Pharm Bull; 2021 Feb; 11(2):385-392. PubMed ID: 33880362
[No Abstract] [Full Text] [Related]
2. NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
Seidi K; Jahanban-Esfahlan R; Monhemi H; Zare P; Minofar B; Daei Farshchi Adli A; Farajzadeh D; Behzadi R; Mesgari Abbasi M; Neubauer HA; Moriggl R; Zarghami N; Javaheri T
Oncogene; 2018 Jul; 37(29):3967-3980. PubMed ID: 29662195
[TBL] [Abstract][Full Text] [Related]
3. RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.
Jahanban-Esfahlan R; Seidi K; Monhemi H; Adli ADF; Minofar B; Zare P; Farajzadeh D; Farajnia S; Behzadi R; Abbasi MM; Zarghami N; Javaheri T
Sci Rep; 2017 Aug; 7(1):8126. PubMed ID: 28811469
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
5. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
6. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells.
Rauca VF; Licarete E; Luput L; Sesarman A; Patras L; Bulzu P; Rakosy-Tican E; Banciu M
PLoS One; 2018; 13(8):e0202827. PubMed ID: 30138430
[TBL] [Abstract][Full Text] [Related]
8. Tumor vascular infarction: prospects and challenges.
Jahanban-Esfahlan R; Seidi K; Zarghami N
Int J Hematol; 2017 Mar; 105(3):244-256. PubMed ID: 28044258
[TBL] [Abstract][Full Text] [Related]
9. Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.
Brand C; Dencks S; Schmitz G; Mühlmeister M; Stypmann J; Ross R; Hintelmann H; Schliemann C; Müller-Tidow C; Mesters RM; Berdel WE; Schwöppe C
J Ultrasound Med; 2015 Jul; 34(7):1227-36. PubMed ID: 26112625
[TBL] [Abstract][Full Text] [Related]
10. An overview on Vadimezan (DMXAA): The vascular disrupting agent.
Daei Farshchi Adli A; Jahanban-Esfahlan R; Seidi K; Samandari-Rad S; Zarghami N
Chem Biol Drug Des; 2018 May; 91(5):996-1006. PubMed ID: 29288534
[TBL] [Abstract][Full Text] [Related]
11. Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.
Seth A; Lee H; Cho MY; Park C; Korm S; Lee JY; Choi I; Lim YT; Hong KS
Oncotarget; 2017 Jan; 8(3):5371-5381. PubMed ID: 28036266
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C
Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410
[TBL] [Abstract][Full Text] [Related]
13. Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
Berdel AF; Schwöppe C; Brand C; Harrach S; Brömmel K; Hintelmann H; Lenz G; Liersch R; Heinzow H; Schliemann C; Mesters RM; Berdel WE; Kessler T
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200318
[TBL] [Abstract][Full Text] [Related]
14. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas.
van Laarhoven HW; Gambarota G; Heerschap A; Lok J; Verhagen I; Corti A; Toma S; Gallo Stampino C; van der Kogel A; Punt CJ
Invest New Drugs; 2006 Jan; 24(1):27-36. PubMed ID: 16379040
[TBL] [Abstract][Full Text] [Related]
15. Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.
Smolarczyk R; Cichoń T; Pilny E; Jarosz-Biej M; Poczkaj A; Kułach N; Szala S
Sci Rep; 2018 May; 8(1):7355. PubMed ID: 29743548
[TBL] [Abstract][Full Text] [Related]
16. Generation of fusion proteins for selective occlusion of tumor vessels.
Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
[TBL] [Abstract][Full Text] [Related]
17. The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.
Porcellini S; Asperti C; Valentinis B; Tiziano E; Mangia P; Bordignon C; Rizzardi GP; Traversari C
Oncoimmunology; 2015 Oct; 4(10):e1041700. PubMed ID: 26451306
[TBL] [Abstract][Full Text] [Related]
18. Role of thymosin beta4 in tumor metastasis and angiogenesis.
Cha HJ; Jeong MJ; Kleinman HK
J Natl Cancer Inst; 2003 Nov; 95(22):1674-80. PubMed ID: 14625258
[TBL] [Abstract][Full Text] [Related]
19. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
[TBL] [Abstract][Full Text] [Related]
20. The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent-DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors.
Drzyzga A; Cichoń T; Czapla J; Jarosz-Biej M; Pilny E; Matuszczak S; Wojcieszek P; Urbaś Z; Smolarczyk R
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
